Neupilept, 250 mg/ml 4 ml 5 pcs

Citicoline is a natural endogenous compound, which is an intermediate metabolite in the synthesis of phosphatidylcholine, one of the main structural components of the cell membrane.

It has a wide range of action – it promotes restoration of damaged cell membranes, inhibits the action of phospholipases, prevents excessive formation of free radicals and also prevents cell death by acting on the mechanisms of apoptosis.

In the acute period of stroke citicoline reduces the volume of brain tissue damage, improves cholinergic transmission. In CHT it reduces the duration of post-traumatic coma and severity of neurological symptoms, and also helps to decrease the duration of recovery period.

In chronic cerebral hypoxia citicoline is effective in treating cognitive disorders such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care. It increases the level of attention and consciousness and reduces the manifestation of amnesia.

Cyticolin is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.

Metabolism

After IV administration, citicoline is rapidly hydrolyzed to choline and citidine and is delivered to various tissues of the body.

Distribution

After administration, cicoline is widely distributed in brain structures with rapid incorporation of the choline fraction into structural phospholipids and the citidine fraction into citidine nucleotides and nucleic acids. Upon reaching the brain, citicoline is incorporated into cellular, cytoplasmic and mitochondrial membranes, taking part in the construction of the phospholipid fraction.

Elimination

Only a small amount of the dose is excreted by the kidneys and through the intestine

Indications

Active ingredient

Composition

Composition (1 ml / 1 ampoule):

How to take, the dosage

Acute period of ischemic stroke and traumatic brain injury (TBI): 1000 mg citicoline every 12 hours from the first day of diagnosis, duration of treatment at least 6 weeks.

The maximum daily dose is 2000 mg.

The recovery period of ischemic and hemorrhagic strokes, the recovery period of CMP, cognitive and behavioral disorders in degenerative and vascular diseases of the brain

Injected v/v or intravenously, 500-2000 mg of citicoline per day. The dosage and duration of treatment depending on the severity of the symptoms of the disease.

Elderly patients

Dose adjustment is not required when Neupilept® is administered to elderly patients.

The drug must be used immediately after opening the ampoule.

Neupilept® is administered by injection/m, intravenous stream (slowly, over 3-5 minutes, depending on the prescribed dose) or by drip (infusion rate – 40-60 drops per minute).

The IV route of administration is preferable to the IV/m route. Repeated administration of the drug to the same site should be avoided when administering in m/m.

Neupilept® is compatible with all types of IV isotonic and dextrose solutions.

Interaction

Cyticoline enhances the effects of levodopa.

Special Instructions

Intravenously Neupilept® is administered slowly (3-5 minutes depending on the dose). When administered intravenously, the infusion rate should be 40-60 drops per minute.

In case of persistent intracranial hemorrhage it is recommended not to exceed the dose of Neupilept® 1000 mg/day, the drug is administered by IV drops at the rate of 30 drops per minute.

Impact on ability to drive vehicles, mechanisms

When using the drug, caution should be exercised while driving vehicles and engaging in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

Contraindications

Side effects

Nervous system and sensory organs: sleep disorders, including. insomnia or somnolence, increased excitability, fatigue, attention disorders, restlessness, anxiety, headache, dizziness, extrapyramidal disorders (rigidity, hypokinesia, hypersalivation, akathisia, acute dystonia), tardive dyskinesia, neuroleptic malignant syndrome, thermoregulation disorders, seizures, stroke (in predisposed elderly patients), blurred vision.

Cardio-vascular system and blood (hematopoiesis, hemostasis): orthostatic hypotension, reflex tachycardia, arterial hypertension, neutro- and thrombopenia, thrombocytopenic purpura.

Gastrointestinal tract: nausea, vomiting, dyspeptic complaints, abdominal pain, constipation, increased liver transaminases.

Genitourinary system: dysmenorrhea, amenorrhea, impotence, erection and ejaculation disorders, anorgasmia, decreased libido, priapism, polyuria, urinary incontinence, edema.

Allergic reactions: skin rash, angioedema.

Other: rhinitis, galactorrhea, gynecomastia, weight gain, hypervolemia (due to polydipsia or inadequate ADH secretion syndrome), hyperglycemia (in diabetic patients).

Overdose

In view of the low toxicity of the drug Neupilept® no cases of overdose have been described.

Similarities